FDA approves pirtobrutinib as first-line treatment for chronic lymphocytic leukemia
- On 2 October 2026 the FDA approved Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia.
- The pirtobrutinib approval also covers small lymphocytic lymphoma, for patients with no known 17p deletion.
- In BRUIN CLL-313, pirtobrutinib cut the risk of progression or death by about 80% versus bendamustine plus rituximab.
- Pirtobrutinib was previously approved only for relapsed or refractory disease.
The US Food and Drug Administration approved Eli Lilly's Jaypirca (pirtobrutinib) on 2 October 2026 for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. The drug moves into first-line treatment after being limited to previously treated patients.
What pirtobrutinib is
Pirtobrutinib is a non-covalent Bruton tyrosine kinase (BTK) inhibitor taken as a 200 mg tablet once daily until disease progression or unacceptable toxicity.
Trial and results
Approval rests on BRUIN CLL-313, a randomized open-label trial of 282 patients assigned equally to pirtobrutinib or chemoimmunotherapy (bendamustine plus rituximab). With a median follow-up of 28 months, median progression-free survival was not reached with pirtobrutinib versus 33.5 months with the comparator (hazard ratio 0.20). Overall survival data are immature; there were 3 deaths (2.1%) versus 10 (7.1%).
Side effects
The most common side effects were upper respiratory infections (27%), rash (22%) and COVID-19 (21%), and serious adverse reactions occurred in 28% of patients. Warnings include infections, bleeding, low blood counts and heart rhythm problems.
Sources: US Food and Drug Administration (FDA), AJMC, American Association for Cancer Research (AACR)
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is new in the FDA approval of pirtobrutinib?
On 2 October 2026 the FDA approved pirtobrutinib (Jaypirca) as first-line treatment for adults with CLL or SLL without a known 17p deletion.
How is pirtobrutinib taken?
Pirtobrutinib is taken as a 200 mg tablet once daily until the disease progresses or side effects become unacceptable.
What did pirtobrutinib show in BRUIN CLL-313?
In BRUIN CLL-313, pirtobrutinib cut the risk of progression or death by about 80% (hazard ratio 0.20) versus bendamustine plus rituximab.
What are the common side effects of pirtobrutinib?
The most common side effects of pirtobrutinib are upper respiratory infections, rash and COVID-19, with warnings for infection, bleeding and heart rhythm problems.
Has pirtobrutinib been shown to extend overall survival?
The effect of pirtobrutinib on overall survival is not yet known because BRUIN CLL-313 survival data are still immature.



